Navigation Links
Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
Date:5/19/2010

CAMBRIDGE, Mass., May 19 /PRNewswire-FirstCall/ -- Idenix Pharmaceuticals, Inc. (Nasdaq: IDIX) announced today that Idenix management will present a corporate overview at the 2010 Citi Annual Global Health Care Conference on Wednesday, May 26, 2010 at 2:00 p.m. ET at the Hilton hotel, New York City and at the Jefferies 2010 Global Life Sciences Conference on June 10, 2010 at 4:00 p.m. ET at the Grand Hyatt hotel, New York City.

The live and archived webcast of the company presentation can be accessed under "Calendar of Events" in the Idenix Investor Center at www.idenix.com.  Please log in approximately 5-10 minutes before the event to ensure a timely connection.  The archived replay will be available on the Idenix website for two weeks following the conference.  

About Idenix

Idenix Pharmaceuticals, Inc., headquartered in Cambridge, Massachusetts, is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of patients with chronic hepatitis C infection. For further information about Idenix, please refer to

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Idenix Retains Worldwide Rights to Develop and Commercialize IDX184 for the Treatment of HCV
2. Idenix Announces Data Presentations at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
3. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
4. Idenix Pharmaceuticals Prices Underwritten Offering of Common Stock
5. Idenix Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results
6. Idenix to Host Conference Call Discussing Second Quarter 2009 Financial Results
7. Idenix Pharmaceuticals to Present at The Deutsche Bank 2009 Health Care Conference
8. Idenix Pharmaceuticals Reports First Quarter Financial Results
9. Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver
10. Idenix Pharmaceuticals to Present at the Canaccord Adams Hepatitis C Conference
11. Idenix Announces Data Presentations from Three HCV Discovery and Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver (EASL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... ... July 01, 2015 , ... The next-generation sequencing (NGS) clinical ... segments, including the molecular diagnostics industry. BCC Research reveals in its new report that ... lower test costs, and a growing need for better diagnostics as part of a ...
(Date:7/1/2015)... July 1, 2015   Neuraltus Pharmaceuticals, Inc. ... of groundbreaking drugs to treat neurodegenerative diseases such ... Robert G. Miller , M.D., Director of the ... California Pacific Medical Center in San Francisco, has been ... $1.5 million to help fund a Phase 2 ...
(Date:7/1/2015)... -- Isagenix International, a leading global health and wellness ... and three Bronze Stevie® Awards at the 2015 Annual ... this month.The American Business Awards ... the U.S. "Winning is a tremendous ... cultivating talent, creating a unified team, and crafting the ...
(Date:7/1/2015)... InferMed , s ... will augment Elsevier ... olutions suite   Elsevier , a world-leading ... announced today the acquisition of  InferMed , a ... InferMed,s Arezzo technology supports clinicians in choosing the most ...
Breaking Biology Technology:NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 2NGS-Based Diagnostics, the ‘Must-Have Platform’, Sends Market Segment CAGRs Soaring According to BCC Research 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4
... Morphotek®, Inc., a subsidiary of Eisai Inc., announced today ... of MORAb-004 for the treatment of metastatic melanoma. The ... that specifically binds to endosialin/tumor endothelial marker-1 (TEM-1), as ... activity at two dosages. The trial is ...
... June 2, 2011 Adeona Pharmaceuticals, Inc. (NYSE Amex: ... for serious central nervous system diseases, announced today positive ... evaluating reaZin along with near-term plans for ... with the Company,s scientific advisors, Adeona intends to conduct ...
... Life Technologies Corporation today announced that preliminary data ... Muenster, Germany, on the Ion Personal Genome Machine (PGM™) strongly ... outbreak in Germany is a new hybrid type of pathogenic ... from the DNA sequencer shows the presence of genes typically ...
Cached Biology Technology:Morphotek®, Inc. Announces Initiation of MORAb-004 Phase II Study in Melanoma 2Morphotek®, Inc. Announces Initiation of MORAb-004 Phase II Study in Melanoma 3Adeona Announces Positive Alzheimer's Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy 2Adeona Announces Positive Alzheimer's Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy 3Adeona Announces Positive Alzheimer's Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy 4Adeona Announces Positive Alzheimer's Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy 5Adeona Announces Positive Alzheimer's Subgroup Analysis that Supports Additional Clinical Study of Proprietary Zinc-Based Therapy 6DNA Sequencing Data Reveals New Hybrid E. coli Strain is Cause of German Outbreak 2DNA Sequencing Data Reveals New Hybrid E. coli Strain is Cause of German Outbreak 3DNA Sequencing Data Reveals New Hybrid E. coli Strain is Cause of German Outbreak 4
(Date:6/17/2015)... , June 17, 2015  Crossmatch™, a leading ... that its U.are.U ® 4500 fingerprint readers ... Eateries, Inc., a San Jose, ... to increase security, improve accountability and reduce fraud ... instant, non-repudiable identity confirmation for employee sign in ...
(Date:6/15/2015)... , June 16, 2015 According ... Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, ... to 2020" published by MarketsandMarkets, The Natural Language Processing ... a CAGR of 18.4% for the forecast period 2015-2020. ...   46 F igures spread   through 155 ...
(Date:6/10/2015)... June 10, 2015 According ... Market by Technology (Ultrasound, TOF, Structured Light, Stereo ... Entertainment, Automotive) and by Geography - Trends & ... the market is expected to reach $3,319.71 Million ... between 2015 and 2020. Browse 71 ...
Breaking Biology News(10 mins):Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 2Togo's Eateries Improve Security and Accountability with Crossmatch Fingerprint Readers 3Natural Language Processing Market Worth $13.4 Billion by 2020 2Natural Language Processing Market Worth $13.4 Billion by 2020 3Natural Language Processing Market Worth $13.4 Billion by 2020 4Natural Language Processing Market Worth $13.4 Billion by 2020 53D Sensor Market Worth $3,319.71 Million by 2020 23D Sensor Market Worth $3,319.71 Million by 2020 33D Sensor Market Worth $3,319.71 Million by 2020 4
... may taint many published studies of so-called prognostic factors--biologic ... may fare during or after treatment, according to a ... Journal of the National Cancer Institute. , In recent ... on prognostic factors for cancer and other diseases. For ...
... of oxygen concentration in the earth's atmosphere shows that a ... mammals the evolutionary boost they needed to dominate the planet, ... lead author of a paper published Sept. 30 in ... measured the abundance of carbon 13, a byproduct of ...
... Fatigue could reduce skills and cause injuries and muscle ... the extra effort required for movement, Monash University researchers ... of Physiology, found when muscles were weakened from overuse ... person couldn't see their limbs. , The study, which ...
Cached Biology News:Biased reporting found in cancer prognostic studies 2Oxygen increase caused mammals to triumph, researchers say 2Can't serve an ace? Could be muscle fatigue 2
Immunogen: Extract of pigmented melanoma metastases from lymph nodes. Storage: -20 C, Avoid Freeze/Thaw Cycles...
alpha N-catenin (C-19)...
... Immunogen: Synthetic peptide derived from the ... 36 protein This peptide sequence is ... another Zymed polyclonal Connexin 36 antibody Cat. ... Connexin 36. Reactivity: Mouse (positive control: ...
Invitrogen's Calcium Phosphate Transfection Kit provides high-quality reagents to enable the introduction of DNA into tissue culture cells via calcium phosphate co-precipitation....
Biology Products: